7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

Please reload

Featured Posts

MaxCyte Highlights Innovations in Scalable, High-Throughput Transient Transfection for Cell Based Assays at the SLAS2013 Conference and Exhibition in Orlando, Booth #428

January 11, 2013

MaxCyte Presents Worldwide Customer Data Demonstrating Unmatched Cell Compatibility and Applicationsin Cell Based Assay


Gaithersburg, Maryland - MaxCyte, Inc.,the pioneer in scalable, high performance cell loading systems, is hosting a series of events at the 2 nd Annual Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition to be held January 13-16, in Orlando, FL. MaxCyte will conduct a tutorial, present a scientific poster, and schedule one-on-one discussions in Booth #428 to demonstrate how the MaxCyte Scalable Transfection Systems can improve the physiological relevance and quality of cellular screening campaigns. 


At the conference, MaxCyte will conduct a tutorial entitled "Streamlined Receptor Screening: Ion Channels, GPCRs and Transporter Screening in Biologically Relevant Cells Using Large-Scale Transient Transfection" on Tuesday, January 15, 2013, at 12:30 PM in rooms Gainesville 1-2 at the Gaylord Palms Resort & Convention Center. In this tutorial, Dr. James Brady, Director of Technical Applications at MaxCyte, will present specific case studies from around the world demonstrating the broad cell type compatibility ofthe MaxCyte STX, including stem cells, primary cells, insect cells, and other difficult-to-transfect cell lines, along with the performance of these transfected cells in downstream applications for cell-based screening and protein production. Highlighted in Dr. Brady’s presentation will be the complementary performance of the MaxCyte flow electroporation technology with downstream assay platforms. 


MaxCyte will also present a scientific poster entitled "Development of Fully Scalable ReporterGene Assaysfor Studying Transcriptional Regulation & Receptor Activation Using Flow Electroporation" (poster # MP 163). MaxCyte scientists will be available at this poster on Monday, January 14, from 1:00 to 3:00 PM for further discussion of these data.






Please reload